Levotonal

Calcium Levofolinate, the active ingredient in Levotonal, is a folate derivative presented as a sterile injectable solution for intramuscular and intravenous use. It provides a reduced form of folic acid that bypasses dihydrofolate reductase inhibition, helping to restore DNA synthesis and cell replication in patients receiving high‑dose methotrexate or with folinic acid deficiency.

GNH USA supplies Levotonal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levotonal is employed in clinical situations where folate rescue or supplementation is required, particularly in oncology and chemotherapy protocols.

- Rescue therapy after high‑dose methotrexate: reduces toxicity and supports rapid cellular recovery. - Reduction of methotrexate toxicity: mitigates adverse effects in patients receiving methotrexate. - Folinic acid deficiency: restores folate‑dependent metabolic processes and normal cell division.

Adverse reactions may occur with Levotonal administration.

Common Side Effects: - Nausea - Vomiting - Mild rash or erythema at injection site - Transient fever - Headache - Mild elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Acute hypotension - Acute renal failure - Severe hepatic dysfunction - Neutropenia - Thrombocytopenia

Levotonal should be used with careful clinical monitoring.

- Assess renal function: adjust or monitor in patients with impaired renal clearance. - Monitor liver enzymes: watch for hepatic toxicity during therapy. - Check for hypersensitivity: discontinue if severe allergic reaction occurs. - Avoid concurrent high‑dose methotrexate without monitoring: coordinate dosing schedules. - Pregnancy considerations: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levotonal may interact with several agents used in oncology and supportive care.

Major Interactions (Avoid): - High‑dose methotrexate: concurrent use may increase folate rescue requirements. - Antifolates (e.g., pemetrexed): may reduce efficacy of calcium levofolinate. - Cytotoxic chemotherapy agents: may alter overall toxicity profile.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of folate compounds. - Proton pump inhibitors: may influence absorption of oral folate derivatives. - Sulfonamides: possible additive bone‑marrow suppression when combined with folate antagonists.